Thalys(SH:603716) Zheng Quan Zhi Xing·2025-07-21 10:21Core Viewpoint - The company, Seer Medical Technology Group Co., Ltd., has decided not to exercise the early redemption rights for its convertible bonds, despite meeting the conditions for redemption due to stock price performance [1][6]. Group 1: Convertible Bond Redemption - The company's stock price has met the condition of being above 130% of the conversion price for at least 15 trading days within a 30-day period, triggering the redemption clause for the "Seer Convertible Bonds" [1][6]. - The board of directors has resolved not to redeem the "Seer Convertible Bonds" early, considering current market conditions and the protection of investor interests [1][7]. - The company will not exercise the early redemption rights for the next three months, and if the redemption conditions are met again after October 21, 2025, the board will reconvene to decide on the matter [1][6]. Group 2: Convertible Bond Issuance and Terms - The company issued 5.4331 million convertible bonds at a face value of 100 yuan each, totaling 534.698 million yuan, with the net proceeds after expenses amounting to 532.698 million yuan [1][2]. - The initial conversion price was set at 16.98 yuan per share, with the conversion period running from March 1, 2021, to August 20, 2026 [2][3]. - The conversion price has been adjusted multiple times, with the latest adjustment reducing it from 12.50 yuan to 12.00 yuan per share, effective from February 6, 2025 [5][6]. Group 3: Compliance and Oversight - The company has adhered to necessary decision-making procedures regarding the non-redemption of the convertible bonds, in compliance with relevant regulations and guidelines [7][8]. - The sponsor institution has confirmed that the decision not to redeem the bonds early is in line with legal requirements and the company's offering documents [7][8].